Clinical and genetic characteristics of 21 Spanish patients with biallelic pathogenic SPG7 mutations.
Autores de CIPF
Participantes ajenos a CIPF
- Baviera-Muñoz R
- Campins-Romeu M
- Carretero-Vilarroig L
- Sastre-Bataller I
- Martínez-Torres I
- Vázquez-Costa JF
- Muelas N
- Sevilla T
- Vílchez JJ
- Bataller L
Grupos de Investigación
Abstract
Spastic paraplegia type 7 (SPG7) is one of the most common hereditary spastic paraplegias. SPG7 mutations most often lead to spastic paraparesis (HSP) and/or hereditary cerebellar ataxia (HCA), frequently with mixed phenotypes. We sought to clinically and genetically characterize a Spanish cohort of SPG7 patients. Patients were recruited from our HCA and HSP cohorts. We identified twenty-one patients with biallelic pathogenic SPG7 mutations. Mean age at onset was 37.4 years (SD ± 14.3). The most frequent phenotype was spastic ataxia (57%), followed by pure spastic paraplegia (19%) and complex phenotypes (19%). Isolated patients presented with focal or multifocal dystonia, subclinical myopathy or ophthalmoplegia. p.Ala510Val was the most frequent pathogenic variant encountered. Compound heterozygous for p.Ala510Val displayed younger onset (p < 0.05) and more complex phenotypes (p < 0.05) than p.Ala510Val homozygotes. Two novel variants were found: p.Lys559Argfs*33 and p.Ala312Glu. In conclusion, spastic ataxia is the most common phenotype found in Spanish patients. Nonetheless, SPG7 analysis should also be considered in patients with less frequent clinical findings such as dystonia or ophthalmoplegia especially when these symptoms are associated with mild spastic ataxia.
Datos de la publicación
- ISSN/ISSNe:
- 0022-510X, 1878-5883
- Tipo:
- Article
- Páginas:
- 118062-118062
- PubMed:
- 34500365
JOURNAL OF THE NEUROLOGICAL SCIENCES ELSEVIER SCIENCE BV
Citas Recibidas en Web of Science: 6
Documentos
- No hay documentos
Filiaciones
Keywords
- Cerebellar ataxia, Neurogenetics, Rare diseases, Spastic paraplegia
Proyectos asociados
Estudios clínicos, bases genéticas y biomarcadores pronósticos en enfermedades raras neurodegenerativas
Investigador Principal: CARMEN ESPINÓS ARMERO
INSTITUTO DE SALUD CARLOS III . 2019
PID10470. No se ingresará dinero en el CIPF. La ayuda consiste en un estudio genómico (long & read-sequencing) para 25 muestras.
Investigador Principal: CARMEN ESPINÓS ARMERO
EASI- Genomics . 2020
De genes a terapia en enfermedades neurodegenerativas y neuromusculares. Concedido a la UV
Investigador Principal: CARMEN ESPINÓS ARMERO
CONSELLERIA DE EDUCACION . 2018